Skip to main content
Smart Investors Daily
GL

NASDAQ · GLSI

Greenwich LifeSciences, Inc.

Healthcare · Biotechnology

$14.94

Down-$1.18 (-7.90%)

Updated Nov 17, 2026, 12:58 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
155.53M
P/E ratio
-7.87
Dividend yield
0.00%
52-week range
$12.51 – $30.26
Volume
75.28K
Avg. volume
77.6K

Price performance · GLSI

GLSI price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

GLSI closed at $14.94 after 20 trading sessions, down 1.78% for the selected period.

Last close
$14.94
Period change
-1.78%
Period low
$14.65
Period high
$19.00
Daily close
View OHLC price history
GLSI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$15.87$15.87$14.56$14.9475.28K
Nov 12, 2026$15.80$16.08$14.40$15.28207.01K
Nov 11, 2026$16.48$16.78$15.995$16.09118.57K
Nov 10, 2026$16.29$16.80$15.80$16.0784.44K
Nov 9, 2026$15.53$17.07$15.1612$16.52157.75K
Nov 6, 2026$14.91$15.75$14.5361$15.1780.86K
Nov 5, 2026$16.19$16.35$14.112$14.65250.16K
Nov 4, 2026$16.46$16.9446$15.76$16.35135.72K
Nov 3, 2026$16.70$17.21$15.89$15.9266.88K
Nov 2, 2026$17.69$17.69$16.23$16.46118.6K
Oct 30, 2026$18.47$18.77$17.04$17.41174.65K
Oct 29, 2026$18.31$19.50$18.08$19.00124.12K
Oct 28, 2026$17.22$18.44$17.00$18.31130.03K
Oct 27, 2026$17.19$17.58$16.6588$17.42224.3K
Oct 26, 2026$16.01$17.44$15.855$17.125118.89K
Oct 23, 2026$15.40$16.09$14.785$16.0386.52K
Oct 22, 2026$16.02$16.77$15.2088$15.4896.44K
Oct 21, 2026$16.41$16.67$16.16$16.5782.27K
Oct 20, 2026$15.10$16.435$15.10$16.24101.57K
Oct 19, 2026$14.84$15.39$14.75$15.21151.94K

Latest GLSI news

The latest Smart Investors Daily articles mentioning GLSI.

GLSI research

Overview

Company profile and research snapshot.

Company profile

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
GLSI recent ratings
DateFirmRatingTarget
Jul 21, 2026HC Wainwright & Co.Buy—
Dec 30, 2025HC Wainwright & Co.Buy—
Apr 21, 2025HC Wainwright & Co.Buy—
Feb 11, 2025HC Wainwright & Co.Buy—
Aug 23, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.